CA2301201A1 - Procede d'inhibition de la cathepsine k - Google Patents
Procede d'inhibition de la cathepsine k Download PDFInfo
- Publication number
- CA2301201A1 CA2301201A1 CA002301201A CA2301201A CA2301201A1 CA 2301201 A1 CA2301201 A1 CA 2301201A1 CA 002301201 A CA002301201 A CA 002301201A CA 2301201 A CA2301201 A CA 2301201A CA 2301201 A1 CA2301201 A1 CA 2301201A1
- Authority
- CA
- Canada
- Prior art keywords
- active site
- procathepsin
- cathepsin
- lys
- asn
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6405—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals not being snakes
- C12N9/641—Cysteine endopeptidases (3.4.22)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/08—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis for Pneumocystis carinii
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Genetics & Genomics (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Neurology (AREA)
- Tropical Medicine & Parasitology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Enzymes And Modification Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
On a identifié une nouvelle structure cristalline de cathepsine K. La présente invention concerne également des procédés qui permettent d'identifier des inhibiteurs de cathepsine K et des procédés qui permettent de mettre au point des inhibiteurs de cathepsine K à l'aide de données structurelles et physiques fondées sur la structure cristallographique de la procathepsine K.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/US1998/014634 WO2000009653A2 (fr) | 1998-08-14 | 1998-08-14 | Procede d'inhibition de la cathepsine k |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2301201A1 true CA2301201A1 (fr) | 2000-02-24 |
Family
ID=22267483
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002301201A Abandoned CA2301201A1 (fr) | 1998-08-14 | 1998-08-14 | Procede d'inhibition de la cathepsine k |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2003527819A (fr) |
CA (1) | CA2301201A1 (fr) |
WO (1) | WO2000009653A2 (fr) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030144175A1 (en) | 1998-12-23 | 2003-07-31 | Smithkline Beecham Corporation | Protease inhibitors |
CN1416346A (zh) | 2000-03-21 | 2003-05-07 | 史密丝克莱恩比彻姆公司 | 蛋白酶抑制剂 |
EP1379634B1 (fr) * | 2001-04-20 | 2017-12-13 | The University Of Georgia Research Foundation, Inc. | Inactivateurs de site actif |
WO2007012180A1 (fr) * | 2005-07-26 | 2007-02-01 | Merck Frosst Canada Ltd. | Inhibiteurs de la cystéine protéase de la famille de la papaïne pour le traitement des maladies parasitaires |
EP2225196B1 (fr) | 2007-11-29 | 2015-01-28 | Merck Canada Inc. | Inhibiteurs de cystéine-protéases pour le traitement de maladies parasitaires |
WO2009087379A2 (fr) | 2008-01-09 | 2009-07-16 | Amura Therapeutics Limited | Composés |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ132798A3 (cs) * | 1995-10-30 | 1999-02-17 | Smithkline Beecham Corporation | Inhibitory proteázy |
CZ206097A3 (cs) * | 1995-10-30 | 1999-02-17 | Smithkline Beecham Corporation | Způsob inhibice kathepsinu K |
-
1998
- 1998-08-14 WO PCT/US1998/014634 patent/WO2000009653A2/fr active Application Filing
- 1998-08-14 CA CA002301201A patent/CA2301201A1/fr not_active Abandoned
- 1998-08-14 JP JP2000565090A patent/JP2003527819A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2000009653A2 (fr) | 2000-02-24 |
JP2003527819A (ja) | 2003-09-24 |
WO2000009653A3 (fr) | 2007-05-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5856116A (en) | Crystal structure and mutants of interleukin-1 beta converting enzyme | |
US6274336B1 (en) | Method of inhibiting cathepsin K | |
Oefner et al. | Structure of human neutral endopeptidase (Neprilysin) complexed with phosphoramidon | |
Orth et al. | Crystal structure of the catalytic domain of human ADAM33 | |
Harmat et al. | The structure of MBL-associated serine protease-2 reveals that identical substrate specificities of C1s and MASP-2 are realized through different sets of enzyme–substrate interactions | |
Marquardt et al. | The crystal structure of human α1-tryptase reveals a blocked substrate-binding region | |
WO2008109871A2 (fr) | Structure cristalline de proprotéine convertase 9 (pcsk9) et utilisations de celle-ci | |
Medrano et al. | Structure of proline iminopeptidase from Xanthomonas campestris pv. citri: a prototype for the prolyl oligopeptidase family | |
US20100030487A1 (en) | THREE DIMENSIONAL COORDINATES OF HPTPbeta | |
Vath et al. | The crystal structure of exfoliative toxin B: a superantigen with enzymatic activity | |
Tang et al. | Crystal structure of earthworm fibrinolytic enzyme component a: revealing the structural determinants of its dual fibrinolytic activity | |
Ljunggren et al. | Crystal structure of the parasite protease inhibitor chagasin in complex with a host target cysteine protease | |
Hasan et al. | Mechanisms of Arg-Pro-Pro-Gly-Phe inhibition of thrombin | |
Dubin et al. | Enzymatic activity of the Staphylococcus aureus SplB serine protease is induced by substrates containing the sequence Trp-Glu-Leu-Gln | |
Stec-Niemczyk et al. | Structural and functional characterization of SplA, an exclusively specific protease of Staphylococcus aureus | |
Kagawa et al. | Model for substrate interactions in C5a peptidase from Streptococcus pyogenes: A 1.9 Å crystal structure of the active form of ScpA | |
Symersky et al. | High-resolution structure of the extracellular aspartic proteinase from Candida tropicalis yeast | |
CA2301201A1 (fr) | Procede d'inhibition de la cathepsine k | |
Fischer et al. | Structural mechanisms of inactivation in scabies mite serine protease paralogues | |
Shin et al. | Crystal structure analyses of uncomplexed ecotin in two crystal forms: implications for its function and stability | |
EP1053304B1 (fr) | Enzyme de conversion cristalline du facteur tnf alpha et ses utilisations | |
US6008033A (en) | Proteases, compositions capable of binding to said site, and methods of use thereof | |
US6842704B2 (en) | Crystalline TNF-α-converting enzyme and uses thereof | |
US20060014934A1 (en) | Crystal structure of factor Vai and method for identifying blood factor Va modulators | |
WO2000077184A9 (fr) | Cristaux de caspase-8 et modeles et procedes correspondants |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Dead |